Philadelphia Biotechs to Strut Their Stuff at JPM 2023

The JP Morgan Healthcare conference (JPM23) is running January 9-13, 2023, in San Francisco. It’s one of the biggest biotech conferences, possibly the biggest, with companies from all over the world coming (or attending virtually) to network with possible investors, present their companies’ progress and breakthrough, announce their annual financial and milestone guidance, and negotiate deals.

In addition to the typical networking and presentations, several of the biggest topics expected to be discussed are the turbulent global economy and the numerous upcoming patent cliffs. According to the JP Morgan Outlook 2023 Report Extract, over the next six years 33 of the biggest-selling drugs will lose their market exclusivity.

In 2023 alone, AbbVie’s Humira, Merck’s Januvia/Janumet and Janssen Immunology (J&J)’s Stelara will all lose patent protection. Respectively, these three drugs brought in $17.3 billion, $1.77 billion and $5.49 billion in the U.S. in 2021. How these companies will respond and how competitors will position themselves to enter those markets will likely be a hot topic.

Numerous representatives from Philadelphia-based biotech, pharmaceutical and life science companies will have a presence at the meeting, conducting one-on-one sessions or making presentations. Here’s a look at just a few.

Avantor’s president and CEO, Michael Stubblefield, is presenting on Monday, January 9 at approximately 9:45 a.m. PT/12:45 p.m. ET. Avantor, based in Radnor, Pa., focuses on several industries, including biotech and healthcare, and is noted as a supplier for the biggest biopharma manufacturers in the world, offering products, services, and expertise. The presentation will be a live audio webcast.

Jazz Pharmaceuticals, which has corporate headquarters in Dublin, with offices in Philadelphia, Palo Alto and Carlsbad, California, Vancouver, British Columbia, and Mississauga, Ontario, is webcasting its corporate presentation on Monday, January 9 at 3:45 p.m. PT/12:45 p.m. ET. Bruce Cozadd, chairman, and CEO will lead the presentation. It will be webcast live.

SFA Therapeutics, fresh off receiving clearance for its Investigational New Drug (IND) application from the FDA to run a Phase Ib study of SFA-001N in patients with non-alcoholic steatohepatitis (NASH), plans to present company information at the Biotech Showcase on Wednesday, January 11 at 10:45 a.m. PT/1:45 p.m. ET. Ira Spector, Ph.D., CEO of SFA, told BioBuzz that the presentation is part of plans to organize a Series A financing round. The company expects the Phase Ib trial to launch this quarter. They will also be presenting some data from its Phase Ib trial of SFA-002 for psoriasis which has a planned readout this quarter as well. SFA is headquartered in Jenkintown, Pa.

GSK’s CEO Emma Walmsley will present on Tuesday, January 10 at 7:30-8:10 a.m. PT/10:30-11:10 a.m. ET. The London-based company’s U.S. headquarters are in The Navy Yard, Pa., and Research Triangle Park, NC. Its consumer-products division is in Moon Township, Pa.

Catalent’s Philadelphia facility is the contract research and manufacturing organization’s North American Center of Excellence for clinical supply packaging. Its headquarters are in Somerset, NJ. Mike Riley, president of Catalent Biologics, will be a featured speaker on Tuesday, January 10, 2023, from 9:15-9:35 a.m. PT/12:15-12:35 p.m. ET. Riley will discuss trends in antibody-drug conjugate (ADC) discovery and development. Riley will also focus on how the company’s SMARTag® ADC platform is innovating the next generation of ADCs.

Amicus Therapeutics’ president and CEO Bradley Campbell is presenting on Monday, January 9 at 2:15 p.m. PT/5:15 p.m. ET. There will be a live audio webcast. Headquartered in Philadelphia, Amicus focuses on rare diseases. Its sole commercial product is Galafold (migalastat) for the treatment of Fabry disease patients with an amenable galactosidase alpha gene (GLA) variant.